Nkarta (NASDAQ:NKTX) Given Buy Rating at HC Wainwright

Nkarta (NASDAQ:NKTX - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They presently have a $18.00 price target on the stock. HC Wainwright also issued estimates for Nkarta's Q4 2025 earnings at ($0.29) EPS and FY2029 earnings at ($0.99) EPS.

Separately, Needham & Company LLC restated a "buy" rating and issued a $11.00 price target on shares of Nkarta in a research report on Thursday. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Nkarta has an average rating of "Buy" and a consensus target price of $14.86.

Nkarta Price Performance

Shares of NKTX traded down $0.15 during trading hours on Thursday, hitting $1.86. 1,063,406 shares of the company were exchanged, compared to its average volume of 1,092,897. The company has a market capitalization of $131.63 million, a PE ratio of -0.99 and a beta of 0.90. The firm has a fifty day simple moving average of $1.99 and a 200-day simple moving average of $2.82. Nkarta has a one year low of $1.31 and a one year high of $11.84.

Nkarta (NASDAQ:NKTX - Get Free Report) last released its quarterly earnings results on Wednesday, March 26th. The company reported ($0.35) earnings per share for the quarter, beating analysts' consensus estimates of ($0.41) by $0.06. Sell-side analysts expect that Nkarta will post -1.7 EPS for the current year.

Insider Buying and Selling at Nkarta

In other news, CEO Paul J. Hastings sold 17,378 shares of the business's stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total transaction of $38,231.60. Following the transaction, the chief executive officer now directly owns 319,859 shares in the company, valued at $703,689.80. The trade was a 5.15 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 8.70% of the company's stock.

Institutional Trading of Nkarta

A number of institutional investors have recently bought and sold shares of NKTX. Invesco Ltd. purchased a new stake in shares of Nkarta during the 4th quarter worth about $30,000. Sequoia Financial Advisors LLC acquired a new position in Nkarta in the fourth quarter worth approximately $31,000. Erste Asset Management GmbH bought a new position in Nkarta during the third quarter valued at approximately $33,000. China Universal Asset Management Co. Ltd. acquired a new stake in Nkarta in the fourth quarter valued at approximately $37,000. Finally, ProShare Advisors LLC bought a new stake in Nkarta in the fourth quarter worth approximately $45,000. Institutional investors and hedge funds own 80.54% of the company's stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.